Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 162

1.

[New anticoagulants - direct thrombin inhibitors].

Brand B, Graf L.

Ther Umsch. 2012 Nov;69(11):643-9. doi: 10.1024/0040-5930/a000342. Review. German.

PMID:
23117667
2.

Dabigatran etexilate: an oral direct thrombin inhibitor for prophylaxis and treatment of thromboembolic diseases.

Baetz BE, Spinler SA.

Pharmacotherapy. 2008 Nov;28(11):1354-73. doi: 10.1592/phco.28.11.1354. Review.

PMID:
18956996
3.

[Direct inhibitors of thrombin, hirudin, bivalirudin, and dabigatran etexilate].

Meddahi S, Samama MM.

J Mal Vasc. 2011 Feb;36(1):24-32. doi: 10.1016/j.jmv.2010.11.005. Epub 2011 Jan 15. French.

PMID:
21239127
4.

Dabigatran etexilate: A novel oral direct thrombin inhibitor.

Blommel ML, Blommel AL.

Am J Health Syst Pharm. 2011 Aug 15;68(16):1506-19. doi: 10.2146/ajhp100348. Review.

PMID:
21817082
5.

Dabigatran etexilate: future directions in anticoagulant treatment.

Schulman S, Reilly PA.

Clin Appl Thromb Hemost. 2009 Sep-Oct;15 Suppl 1:32S-41S. doi: 10.1177/1076029609344199. Epub 2009 Aug 13. Review.

PMID:
19679590
6.

Direct thrombin inhibitors.

Lee CJ, Ansell JE.

Br J Clin Pharmacol. 2011 Oct;72(4):581-92. doi: 10.1111/j.1365-2125.2011.03916.x. Review. Erratum in: Br J Clin Pharmacol. 2011 Oct;72(4):718. Dosage error in article text.

7.

Dabigatran etexilate for thromboembolic prophylaxis in non-valvular atrial fibrillation: the RE-LY study and substudies with commentary.

Waks JW, Zimetbaum PJ.

Expert Rev Cardiovasc Ther. 2013 Nov;11(11):1461-71. doi: 10.1586/14779072.2013.849572. Epub 2013 Oct 23.

PMID:
24147516
8.

New oral anticoagulants: comparative pharmacology with vitamin K antagonists.

Scaglione F.

Clin Pharmacokinet. 2013 Feb;52(2):69-82. doi: 10.1007/s40262-012-0030-9. Review.

PMID:
23292752
9.

Dabigatran etexilate versus warfarin as the oral anticoagulant of choice? A review of clinical data.

Ma TK, Yan BP, Lam YY.

Pharmacol Ther. 2011 Feb;129(2):185-94. doi: 10.1016/j.pharmthera.2010.09.005. Epub 2010 Oct 12. Review.

PMID:
20920530
11.

Pharmacology, pharmacokinetics, and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor.

Stangier J, Clemens A.

Clin Appl Thromb Hemost. 2009 Sep-Oct;15 Suppl 1:9S-16S. doi: 10.1177/1076029609343004. Epub 2009 Aug 19. Review.

PMID:
19696042
12.

[The new Anticoagulants - Relevant Facts for the GP].

Asmis LM.

Praxis (Bern 1994). 2011 Aug 10;100(16):971-6. doi: 10.1024/1661-8157/a000627. Review. German.

PMID:
21833915
13.

Dabigatran etexilate: a possible replacement for heparinoids and vitamin K antagonists?

Guay DR.

Hosp Pract (1995). 2011 Feb;39(1):105-25. doi: 10.3810/hp.2011.02.381. Review.

PMID:
21441766
14.

Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation.

Lip GY, Larsen TB, Skjøth F, Rasmussen LH.

J Am Coll Cardiol. 2012 Aug 21;60(8):738-46. doi: 10.1016/j.jacc.2012.03.019. Epub 2012 May 9.

15.

Dabigatran etexilate in venous thromboembolism.

Ferrer E.

Drugs Today (Barc). 2009 Oct;45(10):715-24. doi: 1396674/dot.2009.45.10.1425728. Review.

PMID:
20069135
16.

Old and new oral anticoagulants for venous thromboembolism and atrial fibrillation: a review of the literature.

Becattini C, Vedovati MC, Agnelli G.

Thromb Res. 2012 Mar;129(3):392-400. doi: 10.1016/j.thromres.2011.12.014. Epub 2012 Jan 20. Review.

PMID:
22264937
17.

New oral anticoagulants.

Galanis T, Thomson L, Palladino M, Merli GJ.

J Thromb Thrombolysis. 2011 Apr;31(3):310-20. doi: 10.1007/s11239-011-0559-8. Review.

PMID:
21327511
18.

[Clinical use of a new class of anticoagulant drugs: the direct thrombin inhibitors].

Puccio D, Montalto S, Valerio MC, Ventimiglia A, Caronia A, Novo S.

G Ital Cardiol (Rome). 2006 Nov;7(11):739-46. Review. Italian.

PMID:
17216915
19.

The evolving role of dabigatran etexilate in clinical practice.

Hellenbart E, Drambarean B, Lee J, Nutescu EA.

Expert Opin Pharmacother. 2015;16(13):2053-72. Epub 2015 Aug 6.

PMID:
26245513
20.

Hospital-based clinical implications of the novel oral anticoagulant, dabigatran etexilate, in daily practice.

Wilcox R, Pendleton RC, Smock KJ, Rodgers GM.

Hosp Pract (1995). 2011 Aug;39(3):23-34. doi: 10.3810/hp.2011.08.576. Review.

PMID:
21881389
Items per page

Supplemental Content

Write to the Help Desk